人源化小鼠模型市场－全球产业规模、份额、趋势、机会和预测，按类型、应用、最终用户、地区和竞争格局划分，2020-2030年预测

2024年全球人源化小鼠模型市场规模为19亿美元，预计2030年将以10.10%的复合年增长率成长至33.8亿美元。人源化小鼠模型是指经过基因工程改造，携带功能性人类基因、细胞或组织的实验动物，因此能够高度模拟人类的生理和病理状况，用于研究目的。该市场的成长主要受全球慢性病发病率上升的驱动，这促使人们需要先进的模型来进行药物发现和开发，尤其是在肿瘤学和传染病研究领域。

主要市场驱动因素

主要市场挑战

主要市场趋势

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球人源化小鼠模型市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依类型（人源化小鼠模型、人源化大鼠模型）
  • 依应用领域（肿瘤学、免疫学与传染病学、毒理学、其他）
  • 按最终用户（製药和生物技术公司、合约研究组织、学术和研究机构）划分
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美人源化小鼠模型市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲人源化小鼠模型市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区人源化小鼠模型市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲人源化小鼠模型市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲人源化小鼠模型市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购（如有）
• 产品发布（如有）
• 最新进展

第十三章：全球人源化小鼠模型市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• Allentown LLC
• Charles River Laboratories International, Inc.
• HBM Holdings
• Horizon Discovery Group plc
• Ingenious Targeting Laboratory Inc.
• Janvier Labs
• Trans Genic Inc.
• PolyGene AG
• Aragen Life Sciences Ltd.
• The Andersons, Inc.

第十六章：策略建议

第17章调查会社について・免责事项

The Global Humanized Mice Model Market, valued at USD 1.90 Billion in 2024, is projected to experience a CAGR of 10.10% to reach USD 3.38 Billion by 2030. Humanized mice models are laboratory animals engineered to carry functional human genes, cells, or tissues, thereby closely replicating human physiological and pathological conditions for research purposes. The market's expansion is primarily driven by the increasing global incidence of chronic diseases, necessitating advanced models for drug discovery and development, particularly in oncology and infectious disease research.

Key Market Drivers

The Global Humanized Mice Model Market is significantly propelled by both substantial technological advancements in genetic engineering and the increasing demand for preclinical drug development. Genetic engineering innovations, particularly advanced gene editing tools, enable the creation of highly refined humanized models that precisely mimic human physiological and pathological conditions. This precision is essential for developing more accurate preclinical tools. For example, according to the Innovative Genomics Institute (IGI), in March 2024, "CRISPR Clinical Trials: A 2024 Update", CRISPR Therapeutics initiated two phase 1 trials in 2023 targeting cardiovascular disease, directly demonstrating the application of these genetic techniques in therapeutic development.

Key Market Challenges

A substantial challenge impeding market expansion in the Global Humanized Mice Model Market is the significant cost associated with the development, maintenance, and ethical oversight of these complex models. These considerable financial requirements directly limit the accessibility and widespread adoption of humanized mice, particularly for smaller biotechnology firms, academic institutions, and emerging research initiatives that operate with more constrained budgets. The extensive investment needed for generating and sustaining these advanced research tools, alongside adherence to rigorous ethical guidelines, contributes to elevated preclinical research expenditures.

Key Market Trends

The increasing adoption of patient-derived xenograft (PDX) models is a significant trend driving the Global Humanized Mice Model Market, owing to their ability to closely mimic human tumor heterogeneity and response to therapies. These models provide a highly predictive preclinical platform essential for oncology drug development and the advancement of personalized medicine strategies. The American Association for Cancer Research (AACR), in its 2024 Cancer Progress Report, highlighted that from July 2023 to June 2024, the FDA approved several new anti-cancer therapeutics, including molecularly targeted drugs, underscoring the continuous output from intensive oncology research that relies on advanced preclinical tools.

Key Market Players

• Allentown LLC
• Charles River Laboratories International, Inc.
• HBM Holdings
• Horizon Discovery Group plc
• Ingenious Targeting Laboratory Inc.
• Janvier Labs
• Trans Genic Inc.
• PolyGene AG
• Aragen Life Sciences Ltd.
• The Andersons, Inc.

Report Scope:

In this report, the Global Humanized Mice Model Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Humanized Mice Model Market, By Type:

• Humanized Mouse Models
• Humanized Rat Models

Humanized Mice Model Market, By Application:

• Oncology
• Immunology & Infectious Diseases
• Toxicology
• Others

Humanized Mice Model Market, By End User:

• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations
• Academic & Research Institutions

Humanized Mice Model Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Humanized Mice Model Market.

Available Customizations:

Global Humanized Mice Model Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Humanized Mice Model Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Humanized Mouse Models, Humanized Rat Models)
  • 5.2.2. By Application (Oncology, Immunology & Infectious Diseases, Toxicology, Others)
  • 5.2.3. By End User (Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Academic & Research Institutions)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Humanized Mice Model Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Humanized Mice Model Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Humanized Mice Model Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Humanized Mice Model Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Humanized Mice Model Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Humanized Mice Model Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. France Humanized Mice Model Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Humanized Mice Model Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Humanized Mice Model Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Humanized Mice Model Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia Pacific Humanized Mice Model Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Humanized Mice Model Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Humanized Mice Model Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Humanized Mice Model Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Humanized Mice Model Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Humanized Mice Model Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. Middle East & Africa Humanized Mice Model Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Humanized Mice Model Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Humanized Mice Model Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Humanized Mice Model Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. South America Humanized Mice Model Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Humanized Mice Model Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Humanized Mice Model Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Humanized Mice Model Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Humanized Mice Model Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Allentown LLC
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Charles River Laboratories International, Inc.
• 15.3. HBM Holdings
• 15.4. Horizon Discovery Group plc
• 15.5. Ingenious Targeting Laboratory Inc.
• 15.6. Janvier Labs
• 15.7. Trans Genic Inc.
• 15.8. PolyGene AG
• 15.9. Aragen Life Sciences Ltd.
• 15.10. The Andersons, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer